200 related articles for article (PubMed ID: 177360)
1. Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation.
Menezes J; Jondal M; Leibold W; Dorval G
Infect Immun; 1976 Feb; 13(2):303-10. PubMed ID: 177360
[TBL] [Abstract][Full Text] [Related]
2. Lymphoblastoid transformation and kinetics of appearance of viral nuclear antigen (EBNA) in cord-blood lymphocytes infected by Epstein-Barr Virus (EBV).
Yata J; Desgranges C; Nakagawa T; Favre MC; De-The G
Int J Cancer; 1975 Mar; 15(3):377-84. PubMed ID: 49325
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.
Menezes J; Leibold W; Klein G; Clements G
Biomedicine; 1975 Jul; 22(4):276-84. PubMed ID: 179629
[TBL] [Abstract][Full Text] [Related]
4. Induction of Epstein-Barr virus-associated nuclear antigen during in vitro transformation of human lymphoid cells.
Leibold W; Flanagan TD; Menezes J; Klein G
J Natl Cancer Inst; 1975 Jan; 54(1):65-8. PubMed ID: 163326
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
Dillner J; Kallin B; Ehlin-Henriksson B; Timar L; Klein G
Int J Cancer; 1985 Mar; 35(3):359-66. PubMed ID: 2982749
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of enhancement of Epstein-Barr virus-induced transformation of peripheral blood lymphocytes by a tumor promoter, TPA, with special reference to lowering of cytotoxicity of T cells.
Harada S; Katsuki T; Yamamoto H; Hinuma Y
Int J Cancer; 1981 May; 27(5):617-23. PubMed ID: 6270019
[TBL] [Abstract][Full Text] [Related]
7. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
Cohen JI; Wang F; Mannick J; Kieff E
Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9558-62. PubMed ID: 2556717
[TBL] [Abstract][Full Text] [Related]
9. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.
Klein G; Sugden B; Leibold W; Menezes J
Intervirology; 1974; 3(4):232-44. PubMed ID: 4376804
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus susceptibility of normal human B lymphocyte populations.
Aman P; Ehlin-Henriksson B; Klein G
J Exp Med; 1984 Jan; 159(1):208-20. PubMed ID: 6319530
[TBL] [Abstract][Full Text] [Related]
12. Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis.
Robinson J; Smith D; Niederman J
Nature; 1980 Sep; 287(5780):334-5. PubMed ID: 6252472
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the transformation of human lymphocytes by Epstein-Barr virus III. Induction of early events by P3HR-1 strain without subsequent immortalization.
Takada K; Osato T
Med Microbiol Immunol; 1981; 170(1):19-26. PubMed ID: 6272076
[TBL] [Abstract][Full Text] [Related]
14. Infection of mouse lymphocytes by Epstein-Barr virus. II. Stimulation of cellular DNA synthesis by EBV in the absence of EBNA induction and cell transformation.
Gross TG; Volsky DJ
Virology; 1984 Feb; 133(1):211-5. PubMed ID: 6322431
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.
Cohen JI; Picchio GR; Mosier DE
J Virol; 1992 Dec; 66(12):7555-9. PubMed ID: 1331538
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effector cells from infectious mononucleosis patients in the acute phase do not specifically kill Epstein-Barr virus genome-carrying lymphoid cell lines.
Patel PC; Dorval G; Menezes J
Infect Immun; 1982 Oct; 38(1):251-9. PubMed ID: 6292093
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of Epstein-Barr virus transformation of human lymphocytes: susceptibility of B lymphocyte subpopulations and differentiation stage of the transformed cells].
Koizumi S
Hokkaido Igaku Zasshi; 1985 Sep; 60(5):724-34. PubMed ID: 3000906
[TBL] [Abstract][Full Text] [Related]
19. Primary EBV infection of human umbilical cord lymphocytes and EBV genome-negative lymphoblastoid cell lines (BJAB and Ramos).
Takimoto T; Sato H; Ogura H
Auris Nasus Larynx; 1986; 13(3):199-205. PubMed ID: 3036055
[TBL] [Abstract][Full Text] [Related]
20. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
